BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33573708)

  • 1. Therapeutic Targeting PLK1 by ON-01910.Na Is Effective in Local Treatment of Retinoblastoma.
    Ma H; Nie C; Chen Y; Li J; Xie Y; Tang Z; Gao Y; Ai S; Mao Y; Sun Q; Lu R
    Oncol Res; 2021 Sep; 28(7):745-761. PubMed ID: 33573708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
    Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
    Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xanthatin Selectively Targets Retinoblastoma by Inhibiting the PLK1-Mediated Cell Cycle.
    Yang J; Li Y; Zong C; Zhang Q; Ge S; Ma L; Fan J; Zhang J; Jia R
    Invest Ophthalmol Vis Sci; 2021 Dec; 62(15):11. PubMed ID: 34901994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
    Lan R; Lin G; Yin F; Xu J; Zhang X; Wang J; Wang Y; Gong J; Ding YH; Yang Z; Lu F; Zhang H
    Lab Invest; 2012 Oct; 92(10):1503-14. PubMed ID: 22890557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
    Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
    Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma.
    Deng H; Jiang Q; Yang Y; Zhang S; Ma Y; Xie G; Chen X; Qian Z; Wen Y; Li J; Yang J; Chen L; Zhao X; Wei Y
    Cancer Biol Ther; 2011 Feb; 11(4):401-9. PubMed ID: 21150280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
    Hikichi Y; Honda K; Hikami K; Miyashita H; Kaieda I; Murai S; Uchiyama N; Hasegawa M; Kawamoto T; Sato T; Ichikawa T; Cao S; Nie Z; Zhang L; Yang J; Kuida K; Kupperman E
    Mol Cancer Ther; 2012 Mar; 11(3):700-9. PubMed ID: 22188812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.
    Feng B; Wang R; Chen LB
    Cancer Lett; 2012 Apr; 317(2):184-91. PubMed ID: 22120675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells.
    Yunoki T; Tabuchi Y; Hayashi A; Kondo T
    Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8353-63. PubMed ID: 24366665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
    Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling.
    Cao YY; Yu J; Liu TT; Yang KX; Yang LY; Chen Q; Shi F; Hao JJ; Cai Y; Wang MR; Lu WH; Zhang Y
    Cell Death Dis; 2018 Jan; 9(2):17. PubMed ID: 29339720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC.
    Wang H; Tao Z; Feng M; Li X; Deng Z; Zhao G; Yin H; Pan T; Chen G; Feng Z; Li Y; Zhou Y
    Biochem Biophys Res Commun; 2020 Dec; 533(3):368-375. PubMed ID: 32962858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide-Hoechst Conjugate Suppresses Tumor Growth
    Liu K; Fang L; Sun H; Pan Z; Zhang J; Chen J; Shao X; Wang W; Tan Y; Ding Z; Ao L; Wu C; Liu X; Li H; Wang R; Su W; Li H
    Mol Cancer Ther; 2018 May; 17(5):988-1002. PubMed ID: 29483218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
    Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
    J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.
    Tandle AT; Kramp T; Kil WJ; Halthore A; Gehlhaus K; Shankavaram U; Tofilon PJ; Caplen NJ; Camphausen K
    Eur J Cancer; 2013 Sep; 49(14):3020-8. PubMed ID: 23790466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase.
    Inoue M; Yoshimura M; Kobayashi M; Morinibu A; Itasaka S; Hiraoka M; Harada H
    Sci Rep; 2015 Oct; 5():15666. PubMed ID: 26503893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.